Rinri Therapeutics Secures $1.78 Million Seed Funding for SNHL Cell Therapy

Rinri’s underlying technology, based on innovative stem cell research, seeks to reverse neuropathic sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear.